Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 15;61 Suppl 5(Suppl 5):S594-600.
doi: 10.1093/cid/civ508.

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

Affiliations

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

Andromachi Karachaliou et al. Clin Infect Dis. .

Abstract

Background: The introduction of MenAfriVac in campaigns targeting people aged 1-29 years across the African meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A (MenA). It is important to consider how best to sustain population protection in the long term.

Methods: We created a mathematical model of MenA transmission and disease to investigate the potential impact of a range of immunization strategies. The model is age structured; includes classes of susceptible, carrier, ill, and immune people (who may be vaccinated or unvaccinated); and incorporates seasonal transmission and a stochastic forcing term that models between year variation in rates of transmission. Model parameters were primarily derived from African sources. The model can describe the typical annual incidence of meningitis in the prevaccine era, with irregular epidemics of varying size. Parameter and structural uncertainty were explored in sensitivity analyses.

Results: Following MenAfriVac introduction at high uptake, the model predicts excellent short-term disease control. With no subsequent immunization, strong resurgences in disease incidence were predicted after approximately 15 years (assuming 10 years' average vaccine protection). Routine immunization at 9 months of age resulted in lower average annual incidence than regular mass campaigns of 1- to 4-year-olds, provided coverage was above approximately 60%. The strategy with the lowest overall average annual incidence and longest time to resurgence was achieved using a combination strategy of introduction into the Expanded Programme on Immunization at 9 months, 5 years after the initial mass campaigns, with a catch-up targeting unvaccinated 1- to 4-year-olds.

Conclusions: These results can be used to inform policy recommendations for long-term vaccination strategies with MenAfriVac.

Keywords: Africa; mathematical modeling; meningitis; vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Diagram of the model for Neisseria meningitidis group A transmission and disease. Each compartment is divided into distinct age classes (not shown). See Table 1 for definition of parameters and Supplementary Material for the full model structure.
Figure 2.
Figure 2.
A typical run of the Neisseria meningitidis group A transmission model.
Figure 3.
Figure 3.
Results from 300 simulations of the initial mass immunization of 1- to 29-year-olds (implemented in year 0). The black dashed line depicts the mean annual incidence.
Figure 4.
Figure 4.
Box plot to show the median, interquartile range, and full range of the predicted annual incidence per 100 000 for different immunization strategies in the 40 years following vaccine introduction from 300 model simulations.

Similar articles

Cited by

References

    1. Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). Hum Vaccin Immunother 2012; 8:715–24. - PubMed
    1. Kristiansen PA, Diomande F, Ba AK et al. . Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013; 56:354–63. - PubMed
    1. Novak RT, Kambou JL, Diomandé FVK et al. . Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012; 12:757–64. - PMC - PubMed
    1. Daugla D, Gami J, Gamougam K et al. . Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 2014; 383:40–7. - PMC - PubMed
    1. Trotter CL, McVernon J, Ramsay ME et al. . Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008; 26:4434–45. - PubMed

Publication types

MeSH terms